Rockefeller Capital Management
SGMO

Rockefeller Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Rockefeller Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.95K Buy
7,900
+5,000
+172% +$1.99K ﹤0.01% 4414
2025
Q4 		$1.22K Hold
2,900
– – ﹤0.01% 4421
2025
Q3 		$1.95K Buy
+2,900
New +$1.56K ﹤0.01% 4093
2023
Q1 		– Sell
-635
Closed -$1K – 3582
2022
Q4 		$1K Hold
635
– – ﹤0.01% 3753
2022
Q3 		$3K Sell
635
-288
-31% -$1.48K ﹤0.01% 3510
2022
Q2 		$3K Sell
923
-1,112
-55% -$4.81K ﹤0.01% 3690
2022
Q1 		$11K Hold
2,035
– – ﹤0.01% 3008
2021
Q4 		$15K Buy
2,035
+44
+2% +$382 ﹤0.01% 2789
2021
Q3 		$17K Buy
1,991
+1,491
+298% +$14.7K ﹤0.01% 2660
2021
Q2 		$5K Sell
500
-2,500
-83% -$28.3K ﹤0.01% 3042
2021
Q1 		$37K Buy
3,000
+2,900
+2,900% +$39.1K ﹤0.01% 2018
2020
Q4 		$1K Sell
100
-910
-90% -$10.7K ﹤0.01% 2775
2020
Q3 		$9K Hold
1,010
– – ﹤0.01% 2045
2020
Q2 		$9K Buy
1,010
+910
+910% +$8.44K ﹤0.01% 1933
2020
Q1 		$1K Hold
100
– – ﹤0.01% 2306
2019
Q4 		$1K Hold
100
– – ﹤0.01% 2003
2019
Q3 		$1K Buy
+100
New +$1.12K ﹤0.01% 1874

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Rockefeller Capital Management's SGMO Position: Q1 2026 in Review

Rockefeller Capital Management increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 172% in Q1 2026, buying an estimated $1.99K and bringing the position to 7,900 shares worth $1.95K. The position accounts for ﹤0.01% of the portfolio, ranked #4414.

Rockefeller Capital Management first reported a position in SGMO in Q3 2019 and has held it in 17 quarters since. The position peaked at $37K in Q1 2021. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Rockefeller Capital Management held 7,900 shares of SANGAMO THERAPEUTICS INC worth $1.95K as of Q1 2026.
  • Rockefeller Capital Management bought 5,000 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $1.99K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4414 holding.
  • Rockefeller Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2019 and has held it in 17 quarters since.
  • Rockefeller Capital Management's SANGAMO THERAPEUTICS INC position peaked at $37K in Q1 2021.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.